Novo Nordisk CEO Jørgensen to Depart With Danish Pharma’s Shares in Freefall

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares have taken a turn since mid-2024, falling by half in one year.

Scroll to Top